Elekta Ab Class B · OMXSTO:EKTA_B
Elekta Ab Class B — Investor Presentation (April 2014)
33 slides from Elekta Ab Class B's investor presentation, Apr 5, 2014
Slide 1: Elekta Investor Breakfast
Elekta Investor Breakfast 5 April 2014, Vienna 1
Slide 2: Important information
Important information This presentation includes forward-looking statements including, but not limited to, statements relating to operational and financial performance, market conditions, and other similar matters. These forward-looking statements are based on current expectations about future event
Slide 3: Elekta ESTRO 2014
Elekta ESTRO 2014 Tomas Puusepp President and CEO 3
Slide 4: Welcome to ESTRO 2014
Welcome to ESTRO 2014 : =
Slide 5: Global market share – two companies
Global market share – two companies Siemens 3% Accuray 8% 40% Elekta Varian 49% 5 Note: Order intake. Sources – company reports. Financial year 2012/13
Slide 6: Market drivers
Market drivers Number of new cancer cases Increased usage of radiation Health care spending therapy Millions Health care spending and installed linacs 12 USA 25 11 Total Linacs / million people USA 63% 10 20 9 8 Europe 30-50% 7 Western Europe 15 6 Japan Men 32% 5 Canada Women Canada 4 10 3 Southern
Slide 7: Q3 report
Q3 report February 27 Strong order bookings – deliveries below expectations in Q3 • Net sales up 1%* in Q3 and 7%* YTD EBITA YTD of SEK 895** (1,053**) M – Leksell Gamma Knife® Strong fiscal year end expected – Weak currency affecting India and Brazil – Reported currency effect: -140 MSEK (-50 MSEK
Slide 8: Leksell Gamma Knife
Leksell Gamma Knife® Confident in the long-term underlying market • Temporarily low volumes in Q3 – Volatile reimbursement in US last year – new rates decided in November • Good order pipeline in North America • Unmatched precision and efficiency • Strong position within Neuro segment • Further inte
Slide 9: Dynamic and leading product portfolio
Dynamic and leading product portfolio Versa HD™ Monaco 5® MOSAIQ ® Flexitron® Leksell Gamma Knife® Esteya® Continue to drive Innovation and Invest in R&D 9
Slide 10: Positioned to capture long-term growth
Positioned to capture long-term growth Comprehensive cancer care solutions Strategic partner in Hardware cancer care Software Partner in Service development of quality care Care Management Training & Education Patient data centralization Consultancy and use 10
Slide 11: Region Europe & AFLAME
Region Europe & AFLAME Ian Alexander Executive Vice President Europe & AFLAME 11
Slide 12: Elekta is the market leader
Elekta is the market leader Order growth Emerging market share CAGR ~45% 14% 06/07 07/08 08/09 09/10 10/11 11/12 12/13 R12 Q3 13/14 Installed base: • ~1,300 linacs • ~60 Leksell Gamma Knife units
Slide 13: Versa HD - exceeding expectations
Versa HD™ - exceeding expectations Accounted for 40% of the volumes on applicable markets in Q3 13
Slide 14: Good growth in established markets
Good growth in established markets • Good growth, particularly in central and southern Europe • Upgrade of maturing installed base in many markets • Opportunities created by exit of Siemens. Elekta capture rate ~50% • Drive usage of radiation therapy in market. In UK only 38% of cancer patients rece
Slide 15: Mixed development in emerging markets
Mixed development in emerging markets Middle East - Strong growth Africa • Structural build-out of • Growing and opportunistic cancer care market • Major order in Iraq • South Africa well established with strong private sector • Major order in Algeria Russia - Lower volumes • RT investment program u
Slide 16: Elekta Brachytherapy
Elekta Brachytherapy John Lapré Executive Vice President 16
Slide 17: Leading products
Leading products Treatment Real-time prostate Electronic Treatment Applicators planning solution brachy for skin delivery LumenCare™ Azure (Lung) ACE Dose Oncentra® New solution Complete LuneRay (Bladder) Calculations Prostate Esteya® Flexitron ® family Fletcher CT/MR 4.2 Shielded (Gyn) 17
Slide 18: Skin cancer - rapidly growing
Skin cancer - rapidly growing 3.5 million new cases • Incidence increase in US per year 8% per year Melanoma 2% • More than all Squamous cancers together cell carcinoma 20% (SCC) Basal cell 78% carcinoma • Drive role of (BCC) radiation therapy 18 Source: Cancer Facts & Figures 2013; skincancer.org
Slide 19: A solution that benefits all stakeholders and creates partnership
A solution that benefits all stakeholders and creates partnership Prefer (non-invasive) Create non-threatening treatment options treatment experience Patient Ability to offer radiation Challenged by growing service by RO at the skin cancer incidence dermatology clinic Dermatology Easy to add a treat
Slide 20: Esteya
Esteya® Attractive economic profile with fast & reliable technology • Highly precise treatment system – Easy to use – Minimal room-shielding requirements – Comprehensive service program • Great opportunity to expand RO service for treating skin cancer – Controlled market rollout progressing – Reimbu
Slide 21: Driving Education & Training
Driving Education & Training Education & Training portal www.brachyacademy.com Promoting exchange of brachytherapy research & knowledge 21
Slide 22: Esteya
Esteya® Commercialization process – shows high potential • Considerable progress in the US – First Esteya installations in California & New York – First patient treated at Los Gatos, California – Several studies for clinical evidence development initiated at key sites • Launched in Australia at ABG,
Slide 23: Elekta Oncology
Elekta Oncology Dee Mathieson Senior Vice President Oncology Business Line Management Kevin Brown Global Vice President Scientific Research
Slide 24: Versa HD, Monaco 5 and Enhanced Integrated Imaging
Versa HD™, Monaco® 5 and Enhanced Integrated Imaging
Slide 25: Versa HD shipped to 30 countries
Higher dose rate Larger high-definition field size Faster MLC leaf speed • Greater versatility • Improved efficiency • Higher quality patient care Versa HD shipped to 30 countries
Slide 26: Clinical application
Clinical application savings Time Agility Complex Level of intensity Simple modulation modulation conformal savings Time FFF High Normal dose/fraction Hypofractionation dose/fraction
Slide 27: Clinical example - Lung
Clinical example - Lung “ This patient with co-morbidities and advanced age was able to successfully complete SBRT treatment with breath-hold technique with a 15-minute treatment time slot. SBRT with flattening filter-free beams can safely deliver high doses per fraction within a short treatment tim
Slide 28: Application convergence
Application convergence Imaging and Treatment treatment planning User Application Oncology experience modules information systems 28
Slide 29: The challenge of motion management
The challenge of motion management Immobilized target Reduced heart Reduced lung anatomy dose volume
Slide 30: Elekta motion management solutions
Elekta motion management solutions Clinical flexibility Intra- fraction imaging Clarity Symmetry Manual Gating 34
Slide 31: Innovation through collaboration
Innovation through collaboration Examples of R&D collaborations Elekta MR/Linac consortium Elekta International IMRT consortium Elekta Synergy® Research Group Elekta Spine consortium Leksell Gamma Knife® Society Elekta Lung Research Group Elekta Clarity consortium Elekta Brachytherapy consortium
Slide 32: Elekta MR Linac Consortium established
Elekta MR Linac Consortium established The MR Linac Consortium aims to: • Demonstrate improved patient outcomes for existing radiation therapy indications • Extend radiation therapy with new treatment techniques and be able to treat more indications Each consortium member will have a MR Linac for: •
Slide 33: Human Care Makes the Future Possible
Human Care Makes the Future Possible